Review date: June 18, 2026
The US Portfolio remains properly aligned with its region/country mandate. All four open positions—Itron, OSI Systems, TransMedics, and Varonis—are U.S.-listed Nasdaq equities, so there is no exchange-discipline or access issue requiring a change. The portfolio is also young: every open position is still inside the protected minimum holding period, meaning we should only close a holding if there is a clear thesis break, serious portfolio-fit issue, or other strong risk-management reason.
Portfolio snapshot
- Itron (ITRI): +2.34% based on stored quote-history performance.
- OSI Systems (OSIS): +10.00%, the portfolio’s strongest contributor so far.
- TransMedics (TMDX): +0.43%, essentially flat but positive in its first week.
- Varonis Systems (VRNS): -0.78%, a small early drawdown that does not change the thesis.
As of the latest market data reviewed, ITRI was around $79.26, OSIS around $217.51, TMDX around $73.22, and VRNS around $33.08. Those levels are broadly consistent with the stored quote-history snapshot used for this portfolio review.
What drove performance this week?
OSI Systems is the clear early leader. The position has benefited from investor confidence in the company’s security, inspection, and optoelectronics exposure. OSI reported fiscal third-quarter 2026 revenue of $453.2 million, record Q3 non-GAAP EPS of $2.60, record backlog of $1.9 billion, and a 1.3x book-to-bill ratio, while reiterating fiscal 2026 guidance. That combination supports the current hold decision, although backlog conversion and contract timing remain key watch items. ([investors.osi-systems.com](https://investors.osi-systems.com/news-releases/news-release-details/osi-systems-reports-fiscal-2026-third-quarter-financial-results?utm_source=openai))
Itron remains a steady smart-infrastructure holding rather than a momentum leader. The company’s first-quarter 2026 update showed revenue of $587 million, down 3% year over year, but adjusted EBITDA increased 5% and free cash flow improved by $11 million. The important portfolio question is whether Itron can convert utility grid-modernization demand into durable margin and cash-flow progress while integrating Urbint and Locusview. ([investors.itron.com](https://investors.itron.com/news-releases/news-release-details/itron-announces-first-quarter-2026-financial-results?utm_source=openai))
TransMedics is still close to its entry level, but the fundamental setup remains active. The company reported first-quarter 2026 revenue of $173.9 million, up 21% year over year, and reiterated full-year 2026 revenue guidance of $727 million to $757 million, implying 20% to 25% growth versus the prior year. The offset is margin pressure: gross margin declined to 58% from 61%, and operating margin was lower as the company invested in growth programs, logistics, and international expansion. ([investors.transmedics.com](https://investors.transmedics.com/news-releases/news-release-details/transmedics-reports-first-quarter-2026-financial-results?utm_source=openai))
Varonis is the only position modestly negative in the stored quote-history record, but the move is small and does not justify closing a new protected holding. Varonis reported first-quarter 2026 SaaS ARR of $683.2 million, up 69% year over year, or 29% excluding conversions, and raised full-year 2026 expectations for SaaS ARR to $814 million to $845 million and revenue to $731 million to $737 million. The portfolio should keep monitoring whether the SaaS transition produces durable free cash flow and improving operating income. ([globenewswire.com](https://www.globenewswire.com/news-release/2026/04/28/3283185/0/en/Varonis-Announces-First-Quarter-2026-Financial-Results.html?utm_source=openai))
Risk concentration
The portfolio is not concentrated in one industry, but it is concentrated in smaller and mid-cap Nasdaq growth equities. That means the main shared risks are valuation sensitivity, execution risk, and market appetite for growth stocks—not a single-sector macro exposure.
- Infrastructure and utilities: ITRI provides exposure to grid intelligence, metering, and utility modernization.
- Security and industrial technology: OSIS adds inspection, defense/security, and optoelectronics exposure.
- Healthcare technology: TMDX adds transplant-device and logistics exposure, with clinical and operational execution risk.
- Cybersecurity software: VRNS adds data-security and SaaS-transition exposure.
This mix is constructive for a U.S. portfolio because the holdings are not all tied to the same end market. However, the portfolio still lacks large-cap defensive ballast, dividend exposure, and traditional value-sector representation. For now, that is acceptable because the portfolio appears intentionally tilted toward innovative U.S. growth companies, but it should be watched if volatility rises.
What to watch next
- ITRI: project-deployment timing, margin durability, free cash flow, and integration progress from Urbint and Locusview.
- OSIS: backlog conversion, order momentum, security-segment margins, and government procurement timing.
- TMDX: gross margin, aircraft/logistics utilization, clinical-program progress, European expansion, and OCS Kidney development.
- VRNS: SaaS ARR excluding conversions, free cash flow, operating income, and whether AI-related data-security demand translates into sustained growth.
Portfolio decision
No positions are being closed this week. All four holdings remain inside the protected minimum holding period, and none currently show a decisive thesis break, poor regional fit, liquidity issue, or excessive concentration problem. The correct action is to keep the portfolio intact, monitor execution, and allow the initial theses more time to develop.
Risk disclaimer: This article is for informational and editorial purposes only and is not financial advice, investment advice, or a recommendation to buy or sell any security. Equity investments can lose value, and readers should conduct their own research or consult a qualified financial adviser before making investment decisions.